Safety and Efficacy of Liraglutide and Semaglutide in Kidney Transplant Recipients
Open Access
- 23 January 2025
- journal article
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (5) , 848-850
Abstract
An abstract is unavailable. This article is available as a PDF only.Keywords
This publication has 12 references indexed in Scilit:
- Semaglutide-associated kidney injuryClinical Kidney Journal, 2024
- GLP-1 Agonism for Kidney Transplant Recipients: A Narrative Review of Current Evidence and Future Directions Across the Research SpectrumCanadian Journal of Kidney Health and Disease, 2024
- Single-center Evaluation of Safety & Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Solid Organ TransplantationProgress in Transplantation, 2022
- Tirzepatide Once Weekly for the Treatment of ObesityNew England Journal of Medicine, 2022
- Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine, 2021
- Metabolic Consequences of Solid Organ TransplantationEndocrine Reviews, 2020
- Comparison of the glucagon‐like‐peptide‐1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective studyDiabetes, Obesity and Metabolism, 2020
- Management of Diabetes Mellitus With Glucagonlike Peptide-1 Agonist Liraglutide in Renal Transplant Recipients: A Retrospective StudyTransplantation Proceedings, 2018
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight ManagementNew England Journal of Medicine, 2015
- Obesity and Cardiac Risk After Kidney Transplantation: Experience at One Center and Comprehensive Literature ReviewTransplantation, 2008